Krystal, Jefferies
According to Benzinga Pro, Krystal Biotech's peer group average for short interest as a percentage of float is 12.98%, which ...
Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today welcomed the European Medicines Agency's (EMA’s) announcement that its Committee for Medicinal ...
Krystal Biotech's VYJUVEK sees strong growth with $1B+ 2025 sales forecast. Check out why I rate KRYS as a Strong Buy and my ...
Russia plans to increase procurements of drugs against rare diseases despite the current tough business environment and ...
The European Medicines Agency’s (EMA) human medicines committee has recommended Krystal Biotech’s Vyjuvek (beremagene ...
The 12-month price targets, analyzed by analysts, offer insights with an average target of $217.33, a high estimate of $221.00, and a low estimate of $212.00. Surpassing the previous average price ...
Investment analysts at Chardan Capital issued their FY2026 EPS estimates for Krystal Biotech in a research note issued to ...
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the ...
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Merus (MRUS – Research Report), Krystal Biotech ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results